news
ViiV agrees to expand access to long-acting HIV PrEP
Under a new agreement, licenced manufacturers will be able to supply generic versions of ViiV’s long-acting cabotegravir HIV pre-exposure prophylaxis (PrEP) medication to developing nations.
List view / Grid view
HIV (Human Immunodeficiency Virus)
news
Afrigen to collaborate with NIAID on mRNA vaccine research
The research collaboration will enable the sharing of technical skills and materials to expedite Afrigen’s goal of mRNA vaccine production.
news
Healthier Together and philanthropic ventures in tropical disease
Europe launches the EU Non-communicable diseases (NCDs) initiative, while GSK and Novartis promise millions to support drug R&D for neglected tropical diseases and malaria.
article
Pharmaceutical C-suite update
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-300x278.jpg)
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-e1652444508201.jpg)
news
Roche announces plans to improve diagnosis and treatments in developing countries
Roche shares initiative commitments that will extend prophylactic treatment access to patients with haemophilia, as well as investments to provide testing capabilities for HIV and Tuberculosis in developing countries.
article
The latest on pharmaceutical counterfeiting
Here, EPR’s Hannah Balfour discusses the latest reports on pharmaceutical counterfeiting and falsification, exploring global and European crime rates, as well as recent counterfeiting incidents reported by Big Pharma.
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
news
Gilead opens paediatric drug development centre in Ireland
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
news
mRNA vaccine candidates for HIV enter Phase I trial
Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.
news
Cabenuva HIV treatment approved for eight week dosing
US FDA approves Cabenuva (cabotegravir, rilpivirine) based on results from the ATLAS-2M Phase IIIb trial which showed every-two-month dosing was non-inferior to once-monthly dosing.
news
First patients dosed in HIV vaccine immunogens trial
Moderna and IAVI take steps towards HIV vaccination, with initiation of a trial dosing patients with HIV immunogens delivered by mRNA.
podcasts
EPR Podcast Episode 8 – Oral biologic drug delivery with Giovanni Traverso, MIT
How close are we to oral biologic drug delivery? Will biomedical devices be essential in overcoming drug delivery challenges? Discover all this and more in this podcast with MIT's Assistant Professor Giovanni Traverso.
news
Three-year Dovato study shows non-inferiority to TAF-based regimens
Dovato demonstrated non-inferior efficacy compared to TAF-based regimens in virologically suppressed adults with HIV-1 in Phase III study.
article
HIV treatment evolution: drug development to meet the modern needs of patients
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
article
Embedding inclusion in pharmaceutical design
In this article, Included’s Raafi-Karim Alidina explores biases in product design, outlining how they impact pharmaceuticals as well as technologies, and practical steps to enhance diversity and ensure inclusion.
news
HIV vaccine fails to protect women against infection
The investigational vaccine tested in sub-Saharan Africa posed no safety concerns but did not provide sufficient HIV protection.
